Side effects for the people, large money for the chosen

We're waiting for an apology for the shrouds, the flatlanders, the wrappers and whoever else. “Effective and 100% safe” for “not seasonal” disease...

We hope that justice will be applied to those who have participated in this device of lies, profited on it, and took paws.

It is worth remembering who among politicians (easy – almost everyone but the Confederate), media, alleged doctors, clergymen and others encouraged, promoted, forced in various ways.

And they inactive do!

And we know that Pfizer only admits to what he has to. The remainder of them are on the Internet. Just read Mr. Malone, Bossche and another specialists. work in Poland is straight borne by the government of PiS and the device allowing specifics to the marketplace with its eternal boss, insensitive to organization rotations...

https://www.pfizer.com/.../pfizer-and-biontech-receive-us...

* * Oh, * *

‘(...) In 2022, Pfizer achieved full gross of $100.3 billion, becoming the first pharmaceutical company to exceed $100 billion in yearly revenue.

However, much of this success was due to the situation of the Covid-19 pandemic. Pfizer's antiviral drug on Covid-19, Paxlovid, was initially advertised as a "wonderful drug" against the virus, and its price increased sharply.

The first price of $2,300 per box rose to astounding $15,000 per box in the early stages of the pandemic. However, request for the drug has declined importantly since then.

On 31 October, Pfizer published its financial study for the 3rd 4th of 2023, which showed a 42% drop in gross year-on-year to $44.247 billion and a 79% decrease in net profit to $5.488 billion.

In the 3rd 4th alone, Pfizer's revenues amounted to $13,232 billion, which means a decrease of 42% compared to the same period last year. The net profit increased from a profit of US$8.608 billion over the same period last year to a failure of US$2.382 billion.

This marked Pfizer's first quarterly failure since 2019, mainly due to the decline in vaccine and drug sales on Covid-19. The sale of vaccines against Covid-19 generated US$1.31 billion in the 3rd quarter, a 70% decrease compared to the erstwhile year.

Similarly, the gross from the drug on Covid-19 Paxlovid amounted to just $202 million in the 3rd quarter, a decrease of 97%. These 2 products brought Pfizer gross of $12 billion in the 3rd 4th of the erstwhile year.

In order to address the crucial shortages in COVID-19, Pfizer implemented a global cost-cutting plan, 1 of which was staff dismissal. (...)’

for: https://www.echemi.com/cms/1489785.html

Wojciech Popiela